Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (spare) for patients with newly diagnosed glioblastoma

HIGHLIGHTS

• who: Ryan Miller from the Foundation (IRCCS), Italy University of Florida, United States have published the research work: Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma, in the Journal: (JOURNAL) of 14/03/2022
• what: The authors report the results of the trial evaluating the safety of TTFields used concurrently with chemoradiation. This study demonstrated that there was minimal impact on deep dose measurements with a mean reduction of planning treatment volume (PTV) dose by 0.5 to 1%. The authors report the final results with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.